Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD)(U01 and U24)

The summary for the Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD)(U01 and U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD)(U01 and U24): -This Funding Opportunity Announcement (FOA) solicits NIH Cooperative Agreement U01 and U24 applications from current awardees and new applicants to continue and expand the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), a multidisciplinary consortium of domestic and international projects. The CIFASD aims to accelerate specific areas of research related to the translation of new or improved capabilities in FASD clinical case recognition (through improved diagnosis, enhanced understanding of the domains of neurobehavioral impairment), interventions (behavior-based, nutritional and/or pharmacological) and prevention, by fostering collaboration and coordinating basic, clinical, and translational research. Wherever possible, the projects should take advantage of the infrastructure that was established in the initial funding period of the CIFASD. -The goals of this Request For Applications (RFA) are to: enhance the capability for definitive diagnosis of fetal alcohol syndrome (FAS) and the broader spectrum of fetal alcohol spectrum disorders (FASD) at different stages of the lifespan; improve understanding of the dysmorphic features in FAS; establish whether there is a relationship between FAS dysmorphic features and the specific underlying impairments in brain function; improve the characterization of the neurodevelopment phenotype of FAS and FASD; develop and test interventions to address neurobehavioral deficits in individuals with FAS and FASD; and develop potential pharmacological agents for FASD prevention, mitigation and/or treatment of FASD. -Applicants must demonstrate that their projects or cores relate to one or more of the integrated themes of the CIFASD consortium. Mutual collaboration between the applicant and one or more consortium investigators is required. New applicants must provide evidence that they have established a collaborative relationship with the consortium.